Articles

A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients

Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Germany
Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Germany
Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Germany
Clinical Trials Unit, Medical Center - University of Freiburg, Faculty of Medicine, Germany
Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Germany
Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Germany
Clinical Trials Unit, Medical Center - University of Freiburg, Faculty of Medicine, Germany;Center for Medical Biometry and Statistics, University of Freiburg, Faculty of Medicine, Germany
Center for Medical Biometry and Statistics, University of Freiburg, Faculty of Medicine, Germany;Université de Nantes, UFR des Sciences Pharmaceutiques, Nantes Cedex, France
Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Germany
Department of Internal Medicine II, University Hospital, Würzburg, Germany
Department of Hematology, University Rotterdam, The Netherlands
Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Center for Medical Biometry and Statistics, University of Freiburg, Faculty of Medicine, Germany
Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center - University of Freiburg, Faculty of Medicine, Germany
Vol. 102 No. 5 (2017): May, 2017 https://doi.org/10.3324/haematol.2016.162693